Skip to main content
Patient preference and adherence logoLink to Patient preference and adherence
. 2023 Sep 28;17:2401–2420. doi: 10.2147/PPA.S412198

A Systematic Review of the Hill-Bone Compliance to Blood Pressure Therapy Scale

Yvonne Commodore-Mensah 1,2,*,, Sabianca Delva 3,*, Oluwabunmi Ogungbe 1,2,*, Lauren A Smulcer 4, Sally Rives 1, Cheryl R Dennison Himmelfarb 1,5,6, Miyong T Kim 7, Lee Bone 1,2,5, David Levine 1,2,5, Martha N Hill 1,2,5
PMCID: PMC10544210  PMID: 37790863

Abstract

Background

Poor medication adherence hampers hypertension control and increases the risk of adverse health outcomes. Medication adherence can be measured with direct and indirect methods. The Hill-Bone Compliance to High Blood Pressure Therapy (HBCHBPT) Scale, one of the most popular adherence measures, indirectly assesses adherence to hypertension therapy in three behavioral domains: appointment keeping, diet and medication adherence.

Aim

To synthesize evidence on the use of the HBCHBPT Scale, including psychometric properties, utility in diverse patient populations, and directions for future clinical use and research.

Methods

We searched electronic databases, specifically CINAHL, PubMed, PsychInfo, Embase, and Web of Science. We included original studies that used the HBCHBPT Scale or its subscales to measure a health outcome, or methodological studies involving translations and validations of the scale. We extracted and synthesized data following the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines.

Results

Fifty studies were included in this review, 44 on hypertension, two on diabetes, and others on other chronic conditions. The scale was successfully translated into numerous languages and used in descriptive and intervention studies. The scale demonstrated sound psychometric properties (Cronbach’s α coefficient 0.75) and sensitivity to capture intervention effects when used to evaluate the effectiveness of high blood pressure adherence interventions. The medication-taking subscale of HBCHBPT performs best and is widely used in diverse contexts to assess medication adherence for chronic conditions.

Conclusion

The HBCHBPT Scale has high versatility globally and has been used in various settings by various healthcare worker cadres and researchers. The scale has several strengths, including high adherence phenotyping capabilities, contributing to the paradigm shift toward personalized health care.

Keywords: medication adherence, treatment adherence, treatment compliance, hypertension, high blood pressure, Hill Bone Medication Adherence Scale, Hill-Bone Compliance to Blood Pressure Therapy Scale

Introduction

Hypertension, or high blood pressure, is a major risk factor for cardiovascular disease (CVD), stroke, renal disease, and dementia.1 Controlling blood pressure requires adherence to prescribed pharmacological and non-pharmacological therapy to reduce the risk of adverse events.2 Adherence is defined as the

Extent to which a person’s behavior–taking prescribed medication, following a diet, and/or executing lifestyle changes-corresponds with agreed-upon recommendations from a health care provider.2

Poor medication adherence, a pervasive patient-level factor associated with not achieving blood pressure targets, is associated with disease progression, avoidable hospitalization, morbidity, and mortality.1 Adherence to drug therapy lowers blood pressure, and reduces the risk for CVD and death.3–5

Approximately 50% to 80% of patients prescribed antihypertensive medications demonstrate suboptimal adherence5 and 30–50% of United States (US) adults do not adhere to drug therapy. Also, 33–69% of medication-related hospitalization in the US are due to poor medication adherence, which costs almost $100 billion a year.6 Nonadherence may occur when the patient does not initiate a new prescribed antihypertensive medication, implement therapy as prescribed by the provider, or persist with treatment as prescribed. Nonadherence undermines the benefits expected from evidence-based drug therapy and ultimately contributes to poor CVD outcomes.

Several interrelated factors influence adherence to drug therapy, including significant pill burden, complex drug regimen, cost of medications, side effects of multidrug antihypertensive regimens, poor patient-provider relationship, and clinical inertia.7,8 Devising appropriate interventions to improve adherence to therapy first requires assessing adherence and the reasons or factors affecting adherence.9 Clinicians often rely on clinical judgment in their assessment of adherence rather than using screening tools and validated instruments for assessing adherence.10

Adherence is measured with direct methods, such as directly observed therapy and measurement of drug metabolites or biomarkers, and indirect methods, such as patient self-reports, questionnaires, pill counts, rates of prescription refills, and electronic medication monitors.6,11 Each method has advantages and disadvantages and differs in accuracy, practicality, cost, and burden.12 There is no consensus on the gold standard for measuring medication adherence, and no single method meets all criteria. However, patient self-report is considered a simple and effective method to assess adherence.13,14

The Hill-Bone Compliance to High Blood Pressure Therapy (HBCHBPT) Scale is an indirect method to assess adherence to hypertension therapy via self-report.15 It is a 14-item scale that assesses patient behaviors for three behavioral domains of hypertension treatment (ie, the three (3) sub-scales): Appointment Keeping (3 items), Diet [salt intake] (2 items), Medication Adherence (9-items).15 The content validity of the original scale was assessed by a relevant literature review and an expert panel, which focused on cultural sensitivity and appropriateness of the instrument for low literacy.15 Internal consistency reliability and predictive validity of the scale were evaluated using two community-based samples of hypertensive adults enrolled in clinical trials of high blood pressure care and control. The standardized Cronbach’s alpha (α) for the total scale were 0.74 and 0.84, and the average interitem correlations of the 14 items were 0.18 and 0.28, respectively. In the initial study, high compliance scale scores, indicating better adherence, predicted significantly lower blood pressure levels and better blood pressure control.

This systematic review aims to synthesize evidence on the use of the HBCHBPT Scale, including psychometric properties, utility in diverse patient populations, and directions for future clinical use and research.

Materials and Methods

Search Strategy

We conducted a comprehensive literature review of databases with the help of an information specialist and according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines.16 We assessed the literature for studies that have used the HBCHBPT Scale.

A search strategy was derived from combinations of keys words that describe the HBCHBPT scales, for instance, “Hill-Bone”, “Hill Bone Medication Adherence Scale”, “Hill-Bone Compliance to High Blood Pressure Therapy”, separated with the “OR” Boolean operator and the search was conducted in the following databases: CINAHL, PubMed, PsychInfo, Embase, and Web of Science. Final searches were conducted on May 18, 2020. We briefly assessed the articles returned at each search to make sure they were relevant and that the articles included the terms in the search strategy. Identified articles were imported into Covidence®,17 for title and abstract screening.

Eligibility

For this review, we included studies that used the HBCHBPT Scale or its subscales in research. This includes original studies in which the HBCHBPT Scale was used to measure an outcome, or methodological studies involving translations and validations of the scale. Additionally, eligible articles had to be peer-reviewed, published in English, and available in full text, although the scale could be administered in the participant’s native language. Articles that only referenced the scale but did not necessarily administer the scale were excluded. Other reviews, study protocols, editorials, and commentaries were excluded.

Data Quality Assessment

The methodological quality of each article was assessed using the Quality Assessment of Diagnostic Accuracy Studies Criteria (QUADAS-2), which allows for transparent rating of bias and assessment of the applicability of primary diagnostic accuracy studies.18 The domains include patient selection, index test, reference standard, flow, and timing. Each of the articles and risk of biased and applicability was judged as “low”, “high”, or “unclear”. Articles were included if judged as “high” and were excluded if the judgment for both bias and applicability assessment were “high”. For articles judged as “unclear”, the two independent reviewers held discussions about these articles, and a third reviewer resolved final judgment and conflicting opinions.

Data Extraction and Synthesis

After title and abstract screening, we obtained full-text versions of screened articles. Two independent authors reviewed the articles for full-text eligibility based on the inclusion criteria. Eligible studies were assessed for quality using the Assessment of QUADAS-2. Data extracted included: author and publication year, country, study setting, sample size, disease, population and setting, age of participants, language, subscales used, method of administration, scoring system, and psychometric properties. Finally, we synthesized the extracted data following the PRIMSA guidelines, and summarized and presented the results in tables.

Results

Search and Study Selection

Following a systematic search in 5 literature databases, 342 articles were identified, 134 duplicates, leaving 208 de-duplicated articles. These 208 articles were assessed for title and abstract eligibility screening, and 112 records were excluded based on the eligibility criteria. We retrieved full-text versions for articles eligible for full-text review and excluded 46 articles due to the following reasons: Abstract only (n=31), Hill-Bone scale not administered (n=7), full-text not available (n=2), review articles (n=4), dissertation study (n=1), and article not published in English (n=1). Full-text eligibility review yielded 50 articles included in the qualitative narrative synthesis. The PRISMA flowchart is shown in Figure 1.

Figure 1.

Figure 1

PRISMA flow chart.

Notes: PRISMA figure adapted from Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Creative Commons.16

Characteristics of Studies

Fifty studies were included in this review and are presented in Table 1, together with the study design, region, population, setting, scale length (full scale versus subscale), method of administration, scoring system, and psychometric properties. A total of 14,364 participants were represented for all the included citations where the sample size ranged from 9 to 2870. Forty-four (44) studies focused on hypertension, two on type 2 diabetes mellitus (T2DM), three on mental or cognitive impairment, inflammatory bowel disease (IBD), Alzheimer’s, and exacerbation of non-specified conditions. Regarding regional comparison, 22 studies were conducted in the Americas, 11 studies in Europe, eight in the Eastern Mediterranean region, five in Africa, two in Southeast Asia, and two in the Western Pacific Region. Twenty-five studies administered the HBCHBPT scale in its original language (English). The remaining studies translated the scale into Polish (n=6), Persian (n=3), German (n=2), Korean (n=2), Arabic (n=2), Chinese (n=2), Xhosa (n=2), Portuguese (n=1), Greek (n=1), Turkish (n=1), Malay (n=1), Afrikaans and Oshiwamb (n=1). All articles included adult patients; only two studies (4%) administered the instrument to caregivers. Most participants were sourced from the community setting, where data collection took place in primary care clinics, and 14 studies were conducted in hospital-based settings. Four papers did not specify a language, and these studies were conducted in countries with a non-English de facto official language.

Table 1.

General Characteristics of Included Studies (N=50)

Author, Year Country Study Design Sample Size (N) Disease Population & Setting Age (Years) Language* Subscale Administration Method Scoring system Psychometric Properties
Abel et al, 201419 USA Cross-sectional study 80 HTN Black women 18–60 English 8-item medication-taking subscale In person, self-administration Scores ranged from 9–36 (9-perfect medication adherence) Cronbach α=0.84
Mean and range of scores: 13.1 ± 4.2
75% adherent: N= 60
25% adherent: N= 20
Al-daken and Eshah, 201720 Jordan Cross-sectional descriptive comparison design 192 HTN Adult patients 52.8; range 20–80) English
Arabic
Full scale (14 items) Interviews 14 items negatively worded and rated on a 4-point Likert scale Scores ranged from 14–56, (56-perfect adherence). Scores were converted to marks out of 100 to categorize patients by adherence level. Cronbach α = 0.79 (Arabic version) The mean (SD) of total adherence to HTN was 87.27 (10.3) out of 100.
Alsolami et al, 201321 Saudi Arabia Cross-sectional study 110 HTN Adult patients at a university hospital 53.6 ±12 Arabic Medication adherence (9 items) and appointment keeping (3-item) subscales. Self-administration Nine questions with four response categories ranging from 1 = None of the time to 4 = All of the time. Cronbach α = 0.76 (Arabic version) for 9-item medication adherence subscale)
Asadullah et al, 201822 Pakistan Cross-sectional descriptive study 401 HTN Adult patients 45.1; range 21–95) NR Excluded non-patients Urdu Full scale (14 items) Interviews and Self-administration 4-point-scale, score ranging from 9 (perfect adherence) to 36 points and dichotomized the responses in ‘perfect adherence’ (9 points) and ‘imperfect adherence’ (>9 points). Cronbach α= NR
336 (83.4%) had imperfect adherence and 65 (16.2%) have perfect adherence.
Mean score: 24.16; Median score: 25.0.
Boulware et al, 200923 USA Cross-sectional 195 HTN Adults from 15 primary care practices 51% were 60+ English Full scale (14 items) Interview Scores range from 14–56 points, Higher scores indicating poorer adherence Cronbach α= NR
Mean(±SD)
Score: 17.8 (±2.6), Range 14–26
Chatziefstratiou et al, 201924 Greece Methodolo-gical study 68 HTN Patients with and without HTN at a general hospital Mean: 65 Greek Full scale Self-administration 4-point Likert-type scale (4=all the time; 1=never) Cronbach’s α = 0.76
Cheong et al, 201525 Malaysia Cross-sectional; instrument validity 262 HTN Adults from two public primary healthcare clinics Mean (±SD) age: 56.3 (±8.7) Malay, but responses were in Chinese/Tamil/Malay Full scale (14 items) Self-administration 4-point Likert scale. Scores ranged from 1 (all the time) −4 (none of the time). Higher scores indicated better adherence. Cronbach α= 0.64.
Cronbach’s α for (items 1, 14, 10, 8, 2), (items 2, 12, 11, 9), and salt intake is 0.64, 0.55 and 0.29, respectively.
Chudiak et al, 201726 Poland Cross- sectional 300 HTN Patients at a University Clinical Hospital Mean (± SD: 71.75 (±7.79) Polish Full scale (14 items) NR Scores range between 14 and 56 points; higher scores=poorer adherence Cronbach α= NR
Full scale (Range: 14–34). Mean (±SD) score: 20.75 ±4.11.
Salt Intake subscale (Range: 3–12; Mean (±SD) score: 4.79 (±1.17). Appointment Keeping subscale (Range: 2–8; Mean(±SD) score: 3.47 (±1.09). Medication Taking subscale (Range: 9–36); Mean(±SD) score: 12.49 (±3.3)
Chudiack et al, 201827 Poland Analytical cross-sectional study 300 HTN/
Cognitive impairment
Adults with HTN on admission at a University Teaching Hospital Mean age: 71.8±7.8 Polish Full scale Self-administration 4-point Likert-type items (1=none of the time, 2=some of the time, 3=most of the time and 4=all the time) Cronbach α = 0.851
Range of scores: 14–34. Adherence level: 63% of the participants
Dennison et a, 200728 South Africa Cross-sectional 403 HTN Black patients in public and private primary care sites Mean age=52 (range: 35–65) Xhosa 10-item, 3- point Likert-type Hill-Bone Compliance Scale Interview Not reported Cronbach α= 0.77
Dharan & Moly, 201729 India Cross-sectional 150 HTN Adult patients in a tertiary care hospital Mean (± SD): 55 (±15) English Full scale (14 items) Interview Four-point Likert scale. Scores ranged from 14–56. Score of 14–28 =good compliance, 29–42 =average, and 43–56=poor compliance. Cronbach α= NR
Etebari et al, 201930 Iran Cross-sectional study 254 HTN Adults with HTN attending a family medicine clinic Mean (± SD): 58.16 ± 10.54 Persian Full scale Self-administration 5-point ‘reversed’ Likert scale: 5 considered as “I never forget”, and the score of 1 determined as “I always forget”. Cronbach α = 0.71.
Scores ranged from 14–51.
Mean overall patient score was 35.96 ± 9.17.
Mean (SD) scores for dietary subsection: 7.84 ± 1.94; Medication: 19.6 ± 5.86; Appointment: 8.52 ± 2.68
Fleig et al, 201831 Germany Prospective observa-tional 1770 HTN Adult patients in practices of 614 internists, general practitioners and cardiologists Mean (± SD): 60.0 ± 13.4 German Medication subscale (9 items) NR Four-point Likert scale. Scores ranged from 9–36
(9 = perfect medication adherence)
Cronbach α= NR
Fongwa et al, 201532 USA Validation study 70 HTN African American women from a federally funded inner-city clinic Mean (± SD): 54 (±8) years, Range: 37–75 years English Full scale (14 items) Interview 14-item Hill-Bone Compliance Scale uses a 4-point Likert scale. Cronbach α= NR Internal consistency reliability coefficients were reported to be 0.74 and 0.84.
Gerber, 201033 USA Cross-sectional 450 HTN African American and White Medicare recipients aged 65+ in a city Mean (± SD): 77±6.65 English Medication- subscale (9 items) Face-to-face interviews; computer-assisted survey Four-point Likert scale. 9–36 (9 reflecting perfect medication adherence) Cronbach α= 0.68
Glasgow, 201234 USA Three-arm RCT 463 Type 2 Diabetes Range: 25–75 years, Dx with DM II, (BMI) of 25 kg/m2 or greater, and at least one other risk factor for heart disease Mean (± SD): 58.4±9.2 English Medication- subscale (9 items) Not reported Dichotomized adherence scores 1 = perfect adherence, 0 = other levels of adherence Cronbach α= NR
Greer & Abel, 201735 USA Mixed methods, Cross-sectional quantitative arm 20 HTN African- American women Mean (± SD): 54 ± (11.6) English Full scale (14 items) Self-administration 4-point Likert scale; Score ranged from 14–56. Higher scores =poorer adherence. Cronbach α= 0.81
Greer & Ostwald, 201536 USA Randomized controlled trial 60 HTN African- American women Mean (± SD): 57.98 ± (12.37) English Full scale (14 items) Self-administration Scores ranged from 14 (perfect adherence-56. A cutoff score of 22 was used to distinguish high and low adherence. Cronbach α=NR
Han et al, 201437 USA Validation study 213 HTN Adults in an inner city Mean (± SD): 68.6 ± (12.3) English Full scale (14 items) Self-administration Four-point Likert scale. Scores ranged from 9–36 (9 = perfect medication adherence) Cronbach α= 0.70
Pearson’s correlation coefficients of HBP SCP-Behavior with existing HBP self-care instruments were moderately strong (r = −0.493 with the Hill-Bone scale; P <0.001 for all correlation coefficients), indicating concurrent validity
Hill-Briggs et al, 200638 USA Randomized controlled trial 65 Diabetes Adult urban African Americans Mean (± SD): 59.5±11.6 English Full scale (14 items) Self-administration 4-point Likert scale; Scores range from 4 to 36, higher scores = higher medication adherence. Cronbach α=Not reported
Mean (± SD): score: 33.1 (±3.9)
Hsu et al, 201039 USA Cross-sectional 94 HTN Chinese American elders from three Chinese churches and one community center Mean (± SD): 75 ± 12.5 Chinese Medication- subscale (9 items) Interview 4-point Likert scale; Scores ranged from 9 to 36; The higher the scores, the lower the compliance Cronbach α= Not reported
The scores ranged from 9 to 22.
Mean (± SD): 10.63 (±2.53)
Ingram and Ivanov, 201340 USA Descriptive correlational design. 121 HTN Community - African American community members Mean (± SD)59.75 (± 7.94) Range 50–87 English Full scale (14 items) Self-administration 4-point Likert scale; 14–56 higher scores indicating less adherence. Cronbach α = 0.73.
Mean: 24, and 50% non-adherent
Karademir et al, 200941 Turkey Validation study 200 HTN Primary health clinic- Adult patients 58% of partici-pants were >61 y/o Turkish Full scale (14 items) Interview 4-point Likert scale; lower scores= better adherence Full scale: Cronbach α = 0.72
Medication subscale: (Cronbach α =0.83
Salt intake subscale: (Cronbach α= 0.62
Kim et al, 200742 USA Cross-sectional 208 HTN Community - Korean Americans in a metropolitan area Mean (± SD): 52.6 ± 5.6 English and Korean Medication subscale (4 items) Interview 4-point Likert scale; lower scores= better adherence Medication subscale: Cronbach α =0.74
53.8% of participants endorsed at least 1 type of nonadherent behavior.
Kosachack et al, 201043 Germany Comparison and validation study 353 HTN General practice - Adults attending 23 German general practices Mean (± SD): 64 ± 11 German Full scale (14 items) Telephone interview 4-point Likert scale; low score = better adherence, dichotomized the responses in “perfect adherence” (9 points) and “imperfect adherence” (>9 points) Cronbach α = 0.73.
Krousel-Wood et al, 200544 USA Cross-sectional survey 239 HTN Community - Patients attending the hypertension section of the Internal Medicine Clinic in a large multispecialty group practice Mean: 69; Men Mean (± SD): 68.3 ±11.2, Women Mean (± SD): 69.8 ± 13.0 English Full scale (14 items) Self-administration 4-point Likert scale; higher scores= poor adherence Full scale: Cronbach α = 0.43.
Medication subscale:
Cronbach α=0.68
Salt intake subscale: Cronbach α= 0.49
Krousel-Wood et al, 200845 USA Cross-sectional survey 210 HTN Community - patients attending the HTN section of an established urban multispecialty group practice after Hurricane Katrina Mean: 63.6 English Medication subscale (9 items) Self-administration 4-point Likert scale; higher scores= poor adherence Cronbach α = NR
46% of the patients had less-than-perfect adherence to antihypertensive medications in the year following Hurricane Katrina.
Krousel-Wood et al, 201346 USA Cross-sectional survey, prospective cohort study 394 HTN Adults > 65 years from a large managed care organization Mean (± SD): 76.6 ± 5.6 English Medication subscale(9-items) Self-administration 4-point Likert scale, higher scores= poor adherence Cronbach α = NR
Concordance statistic = 0.66 (95% CI 0.622–0.674)
Lambert et al, 200647 South Africa Validation study 98 HTN Community Patients from peri-urban community health centers or a government work site in Mean (± SD): 52 ± 7.6 Xhosa Full scale (14 items); 10-item adapted scale Interview 4-point Likert scale; lower scores= higher adherence 10-item scale:
Cronbach α = 0.79
Salt-intake subscale: Cronbach α = 0.41.
Medication subscale(8-items):
Cronbach α=0.76
Mafutha and Wright, 201348 South Africa Cross-sectional 101 HTN Primary health clinic - Patients living in a city and attending one of the three primary healthcare clinics Range 20–80 English Full scale (14 items) Interviewer-assisted (face-to-face interviews with fieldworkers fluent in local languages) 4-point Likert scale; higher scores= better compliance label 80% and above as good compliance, between 70% and 79.9% as moderate compliance and 69.9% and below as poor compliance Good compliance = 70% Moderate compliance = 23%
Low compliance = 7%
Manze et al, 201549 USA Prospective cohort 819 HTN Hospitalized adults at an urban safety-net hospital Mean: 59.6 English Salt-intake subscale Self-administration Higher score indicates worse diet, range 1–12 Cronbach α = NR
Maslakpak and Safaie, 201650 Iran Randomized controlled clinical trial study with a pretest-posttest design 123 HTN Community-dwelling adults in a city Control group: 50.54 (mean)±8.14, Text message group: 53.68 (mean) ± 6.94, Reminder card group: 50.29 (mean) ± 10.51 Not specified Full scale (14 items) Interviewer administered 1 = never, 2 = occasionally, 3 = often, and 4 = always Cronbach α = NR
Maslakpak et al, 201850 Iran Single-blind randomized, parallel-group controlled trial 100 HTN Adult patients referred to a clinical-educational center 18–60 years Persian Full scale 4-point Likert scale: never (1), occasionally (2), often (3) and always (4) Cronbach α = 0.87, 0.94, 0.79, 0.88, respectively for total treatment, medication, low sodium regimen and medical appointments adherence. 4-point Likert scale: never (1), occasionally (2), often (3) and always (4)
Mutneja et al, 202051 India Observational cross-sectional study 452 HTN Patients prescribed antihypertensives attending cardiology and geriatrics outpatient clinics Mean ± SD: 54.6 ± 13.7 years Not Specified Full scale Self-administration 4-point Likert-type scale (1=never, 4=always) Cronbach’s α: overall = 0.7; Subscales: Salt intake = 0.7; appointment keeping = 0.8; medication adherent = 0.7
Mean inter-item correlation: 0.341; Kaiser-Meyer-Olkin (KMO): 0.591
Nashilongo et al, 201752 Namibia Descriptive cross-sectional observational study/validation study 120 HTN Primary health clinic - Adults from public primary health clinics in four sub-urban townships Mean (± SD): 47.3 ± 11.1 Afrikaans and Oshiwamb Modified 12-item Namibian version (items 6 and 12 from original scale removed) Interview 4-point Likert scale; Lower scores=better compliance.
Replies to questions with a mean score > 2 indicated poor compliance.
Cronbach α = 0.695
Ndumele et al, 201053 USA Cross-sectional survey 141 HTN Primary health clinic - African American (AA) and Non-Hispanic White patients AA median = 64 (59–73 range), White median = 67 (57–71 range) English Full scale(14-items) Interviewer administered 4-point Likert scale; lower scores=better adherence. Cronbach α = NR
Nguyen et al, 200954 USA Cross-sectional 235 Inflammatory Bowel Disease (IBD) Primary health clinic - IBD patients from outpatient clinic Mean (± SD): 41.2± 14.2 English 10 items along with 2 behavior domains: medication-taking and prescription refill (8 items), and appointment keeping (2 items) Telephone interview 4-point Likert scale; Scores ranging from 10 (most adherent/least non-adherent) to 40 (least adherent/most non-adherent). Adherence was also dichotomized with a threshold score of less than 16 reflecting adherence versus non-adherence. Cronbach α = NR
Nogueira-Silva et al, 201655 Portugal Validation study One group with 9 people HTN Clinic - Adults in HTN clinic Not reported Portuguese Full scale (14 items) Self-administration 4-point Likert scale; 1 = Always, 4 = Never. Lower scores=better adherence Cronbach α = NR
Rose et al, 201456 USA Descriptive correlational design 98 Serious Mental Illness Community - Psychiatric Treatment program Mean (± SD): 51.84 ± 8.79, 31–75 (range) English Full scale Interview 4-point Likert scale; Lower scores=better adherence Cronbach α = NR
Mean (± SD): score = 21.21 (± 4.41)
Sarfo et al, 201857 Ghana Cross-sectional design 2870 HTN and/or Type 2 DM 5 Hospitals - participants with HTN with or without diabetes Mean (± SD): 58.9 ± 16.6 English Full scale (14 items) Interview 4-point Likert scale; 1=none of the time, 4=all of the time; higher scores=poorer adherence Cronbach α = NR
Shawler et al, 201958 USA Longitudinal predictive 51 dyads
Analysis of Hill-Bone scale of 18 hypertensive mother-daughter dyads.
HTN Older mother-adult daughter dyads recruited from 4 senior citizen centers in an urban area Mean: mothers; 781; daughters: 52.5. English Full-scale Interviews Not reported Cronbach’s α = 0.69 and 0.68 at baseline and follow-up, respectively
Mean scores:
At baseline:
Mothers: 52.0 ± 2.6
Daughters: 48.5 ± 4.0
At 6-month follow-up:
Mothers 52.4 ± 2.5.
Daughters: 49.2 ± 2.5
Song et al, 201159 USA Validation study 525 HTN Community - Korean Americans from two community-based HTN intervention trials Mean (± SD): 52.5 ± 5.42 Korean 8-item modified medication subscale Face-to-face interviews with bilingual interviewers 4-point Likert scale; 1=none of the time, 4=all of the time; Lower scores=better adherence Cronbach α = 0.76
Uchmanowicz et al, 201660 Poland Validation study 117 HTN Private medical center Mean (± SD): 60.7± 12.41 Polish Full scale (14 items) Self-administration 4-point Likert scale; 1=none of the time, 4=all of the time; Lower scores=better adherence Full Scale Cronbach α = 0.851.
Medication subscale
Cronbach α = 0.78
Uchmanowicz et al, 201861 Poland Prospective, cross-sectional, and analytical study 186 HTN Hypertensive elderly patients at the hypertension clinic Mean age: 71.05±7.47 years Polish Full-scale Interview Not reported Overall mean score= 20.39±4.31 points.
Mean score in the subscale analyses: reduced sodium intake =4.75±1.33 Appointment keeping = 3.45±1.07 Medication taking = 12.19±3.46
Uchmanowicz et al, 201862 Poland Cross-sectional study 150 HTN Hypertensive adult patients at the University Clinical Hospital Mean: 72.1 ±8.0 Polish Full scale Interviews 4-point scale: “none of the time=1”, “some of the time=2”, “most of the time=3”, and “all the time=4” Cronbach α = 0.851.
Scores ranged from 14 to 32 points. The median was 19 points. The first and third quartiles were 17 and 22.
Mean overall score: 20.19 ±4.05.
Subscale analysis:
Reduced sodium intake: 4.82 ±1.09; Appointment keeping: 3.33 1±19; medication taking: 12.05 ±3.08.
Uchmanowicz et al, 201963 Poland Cross-sectional study 160 HTN Adult patients hospitalized at the Hospital in a city 65–78, Mean, 72.09 ±7.98 Polish Full scale Self-administration Modified scale: “none of the time”, “some of the time”, “most of the time”, “all the time”, “not applicable”, and “do not know”. Cronbach α = NR
Scores ranged from 14 to 32 points.
Mean overall score: 20.24 ±4.01. Median score: 19.5.
Wang et al, 201564 USA Cross-sectional correlation study 45 Alzheimer’s Adult caregivers and Alzheimer’s patients at university geriatric clinics and local communities in a large city. Patients: Mean (± SD): 81.3 ± 7.9
Caregivers: Mean (± SD): 66.8 ± 10.5
English 6-item version of the full scale Interview 5-point Likert-type scale (1 = never, 5 = all the time), responses to both measures were reverse coded; higher scores = higher adherence to medications and appointments Cronbach α = 0.88.
Zabihi et al, 201265 Iran Descriptive study 120 HTN Hospital clinics - Adults attending clinics affiliated with the hospitals 40–60 (range), 64.2% >51 y/o Not reported Full scale (14 items) Interview NR
To classify adherence scores, scores of patients in each subscale were calculated, divided by the total score of the same subscale, and finally multiplied by 100
Cronbach α = 0.71.
Zare et al, 201966 Iran Matched RCT 101 HTN Outpatients referred to two heart clinics Mean (range): Intervention: 43.17 (26–60); Control: 44.24 (27–58) Persian Full scale Self-administration during clinic visits Not Reported Cronbach α = 0.71
Zwar et al, 201767 Austra-lia Pretest posttest 47 HTN Adults at general practices Mean (± SD): 62.5 ± 19.2 English Full scale (14-items) Interview NR Cronbach α= NR

Notes:*Languages scales were translated into or administered in, if applicable.

Abbreviations: HTN, Hypertension; DM, Diabetes Mellitus; RCT, Randomized Controlled Trial; NR, Not Reported; HBP, High Blood Pressure.

Of 50 records, 26 were self-administered (1 computer-assisted), and 30 were interviewer-administered (2 via telephone). Additionally, 38 studies used the full scale, while the remainder used specific subscales: medication taking (n=10), salt intake (n=1), and appointment keeping (n=1). Scoring systems were adapted from the original scale, where the following ranges were reported: 9–36 and 14–56. A four-point Likert scale was used in 49 studies where higher scores indicated better adherence. One study used reverse coding on a five-point Likert scoring method. The average Cronbach’s α coefficient was 0.75 (range: 0.43–0.85). In the 21 cases where Cronbach’s α measures were not reported, most authors endorsed internal consistency of the original scale.

Randomized Controlled Trials That Measured Adherence with the HBCHBPT Scale

Table 2 features six randomized controlled trials related to hypertension and diabetes that used the HBCHBPT Scale. The results suggest that in adults with hypertension and diabetes, health behaviors and health outcomes improved specifically related to medication adherence for glycemic and BP control. A 4-arm RCT of 123 community-dwelling adults showed significant treatment compliance differences between the control and intervention groups (P < 0.0001).50 Five RCTs focused on education and technology as methods for improving adherence to treatment and saw favorable outcomes in the intervention groups. Technology tools featured text messages, a self-care application, and a self-management website. The education sessions focused on two main behaviors: medication taking and diet management. Only two studies measured objective outcomes: blood pressure36 and hemoglobin A1c.38 The remaining four studies used psychometric scales such as the HBCHBPT to measure certain self-care behaviors. Although the educational interventions were effective, they focused more on the “medication taking” and “proper diet” items versus the “appointment keeping” domain.

Table 2.

Randomized Controlled Trials Measuring Adherence in Hypertension (n=4) and Diabetes (n=2) Treatment

Author Condition Purpose Intervention Effect Size (Cohen’s d) Medication Adherence/Clinical Outcome
Glasgow et al, 201234 Diabetes To address 3 self-management behaviors for adults with diabetes: medication adherence, exercise, and food choices, using the diabetes self-management website. My Path/Mi Camino, a computer-assisted diabetes self-management (CASM) intervention vs a CASM plus human support (CASM+) condition. d for Medication adherence=0.12 at 4 months, 0.13 at 12 months comparing CASM vs CASM+ Internet conditions improved health behaviors significantly vs usual care over the 12-month period (d for effect size = 0.09–0.16)
Greer & Ostwald, 201536 Hypertension To improve outcomes for 60 African American women with hypertension. 90-minute educational sessions offered once a week for 6 weeks to groups of 8 to 12 women. Participants randomized to a wait-list control group received only usual care from their healthcare provider. After data collection, participants in the wait-list group were offered the classes, and 11 of 30 women enrolled, were shown a DVD, and received the lecture materials, pamphlets, and handouts. A significant favorable overall main effect (time) was found for systolic blood pressure (F3, 174 = 11.104, P = 0.000) and diastolic blood pressure (F3, 174 = 4.781, P = 0.003) for both groups.
Hill-Briggs et al, 200638 Diabetes To examine, in a sample of urban African Americans with type 2 diabetes, the association of social problem-solving with glycemic control and health behaviors. Participants underwent standardized interviews, physical assessment, and laboratory testing. They also received additional assessments of health behaviors and psychosocial factors. Difference between mean A1C for the Above Average avoidant style group, as compared to the Below Average avoidant style group, was 2.2 (p = 0.03, 95% CI = 0.20–4.31), indicating significantly worse glycemic control in the Above Average group. Linear regression showed that for every 1.62 increase in A1C in the Avoidant group, there was a –0.95 decrease in medication adherence.
Maslakpak & Safaie, 201650 Hypertension To compare the effectiveness of short message service (SMS) to reminder cards about medication adherence in patients with hypertension. 3-month intervention with three groups: the control group received the standard education; SMS groups were sent 6 messages a week and the reminder card group. Also, all the patients were asked to visit the clinical center 6 times. Medication adherence for three groups: control (46.63±2.99), SMS (57.70±2.75) and the reminder cards (57.51±2.69) after the intervention.
Maslakpak et al, 201850 Hypertension To evaluate the effectiveness of family involvement in patient education on hypertension management. The participants in the control group were given routine education. The control group received the paper-based educational materials and all participants completed the Hill-Bone Scale and their blood pressure was measured at the end of the intervention. Mean medication adherence scores: control group: 21.72 ± 2.20, family-oriented group: 13.44 ± 3.26, patient-oriented group: 16.64 ± 2.59 and patient and family-oriented group: 12.36 ± 2.36; p < 0.0001. Treatment compliance was best in the patient and family-oriented groups compared to other groups after the intervention.
Zare et al, 201966 Hypertension To evaluate the effect and acceptance of an educational self-care application. The control group participants received the routine care and underwent no interventions. The patients in the intervention group were asked to use the application for eight weeks. They were also asked to measure and save their BP in the application every two weeks. There was a significant difference between the intervention and control groups regarding the mean score of self-care behaviors (4.13 ± 0.23 versus 3.18 ± 0.27, p < 0.001). Additionally, a significant difference was observed between the two groups concerning the mean scores of the two subscales of self-care behaviors, including “medication taking” and “proper diet”.

Discussion

The Hill-Bone Compliance to High Blood Pressure Therapy Scale is one of the most widely used indirect measurements of adherence to hypertension therapy.68 Our systematic review aimed to synthesize evidence on the use of the scale, including its psychometric properties and utility in various patient populations. Although the majority of the articles in this systematic review applied HBCHBPT scales to patients with hypertension, the scales have also been used with other disease conditions such as diabetes, Alzheimer’s’ disease, and inflammatory bowel disease. The Cronbach’s α for studies that reported this statistic ranged from 0.62 to 0.88. In addition, we observed variation in the use of the 14-item scale or the 9-item medication adherence subscale. The HBCHBPT scales have also been used in randomized clinical trials to measure improvements in medication adherence and the prediction of improved blood pressure measurements and control. The high predictive validity of the scale is a distinct strength of this scale and the reason for its popularity.

Hypertension is a leading independent risk factor for cardiovascular diseases, renal disease, stroke, and death.1 Self-report measures of hypertension are strongly associated with adverse cardiac events, including myocardial infarction, coronary heart disease death, and stroke.69 However, there are limitations, such as recall bias and social desirability. One of the most important factors associated with hypertension control is medication non-adherence, which increases the risk of severe cardiovascular disease and death from 50–80%.70 About half of the persons with cardiovascular diseases or major risk factors (ie, hypertension) have poor adherence,71 and only about half of persons with hypertension achieve blood pressure control. The HBCHBPT scale was developed as an indirect method of measuring hypertension medication adherence, including items on medication adherence, appointment keeping, and diet. The brief instrument, which can be administered by self-administration or interview in less than five minutes, is designed to augment care in the clinical setting by assessing for self-reported adherence to hypertension therapy, facilitating the planning of individualized hypertension care, and research design adherence interventions.15

A subsequent version of the original scale, the Hill-Bone Medication Adherence Scale (HBMAS), has recently been derived from the full scale to specifically measure medication adherence.72 The newer instrument includes 9 items assessing medication adherence in the original HBCHBPT scale. Several studies have demonstrated the reliability of the 9-item medication adherence subscale.21,33,73,74

This systematic review revealed that the scales’ utility has expanded from assessing adherence to hypertension and/or cardiovascular disease medication to include other conditions such as diabetes, Alzheimer’s, and inflammatory bowel disease. This is important as medication non-adherence is equally vital in chronic conditions such as stroke, diabetes, and Alzheimer’s disease. For instance, medication adherence in patients with stroke is 64%,75 and about 45% in patients with diabetes,76 about 17–100% in older adults with Alzheimer’s dementia.77 In inflammatory bowel disease, non-adherence has been found to range from 7%-72%78 and varies between 17–74% for chronic kidney disease.79

The reproducibility of the scales in various settings and populations is notable This review showed that the scale was administered in different populations, including adults with various chronic diseases, cognitive impairments, older adults, and African American and Asian populations. Based on these diverse populations, the lowest Cronbach’s α observed among the studies validating the scales in other populations was 0.62, while the highest was 0.88. This range of Cronbach’s α is desirable as extremely high internal consistency ≥ 0.95 reduces sensitivity and room for capturing changes due to an intervention, hence a less desirable feature of an intervention evaluation measure.80,81 This range of Cronbach’s α was compared to that of the full HBCHBPT scale, which was 0.74 and 0.84, and the average interitem correlations of the 14 items of 0.18 and 0.28, respectively.15 In this review, although studies have reported relatively high reliability, validation studies are needed to assess the scales’ appropriateness in various other populations. Additionally, the dearth of data on the optimal recall period limits and the lack of a gold-standard self-report measure limits the process of selecting a medication adherence scale,71 including the HBCHBPT scale. Beyond the HBCHBPT scale, the most widely used validated scales to measure medication adherence are the Morisky Medication Adherence Scale (MMAS-8),82 the Morisky-Green-Levine test,83 the Medication Adherence Self-Efficacy Scale (MASES)84 and The Brief Medication Questionnaire.85

There are various reasons to choose the Hill-Bone scales for use in research and practice. The ease of use and brevity of the scales may have contributed to their administration in various settings. This review showed that the HBCHBPT scales were used in primary health centers, specialty clinics, hospitals, and community health centers. This has significant implications for the clinical use of the scales. Its performance in this myriad of clinical settings suggests stability in its ability to accurately estimate self-reported medication adherence regardless of clinical setting or patient population.

Furthermore, the HBCHBPT scale demonstrated adequate sensitivity to capture any change due to intervention with varying degrees of intensity. The early investment in efforts to establish the predictive validity of the scale by the original developers resulted in valuable measures in both descriptive and intervention research settings.

In addition, the scale permits self-administration; in this review, most of the articles reported self-administration, and fewer were interviewer-administered. This has significance for using these scales in low- and middle-income countries (LMICs) where medication adherence is notably lower due to various factors, including weaker health infrastructure and healthcare access inequality. Thus, there is a need to evaluate medication adherence appropriate to LMICs where the burden of chronic diseases is increasing, and challenges with medication utilization are higher.86 Finally, the scale may be obtained free of charge upon request for permission for their use; this would further improve the scales’ utility, particularly in low-resource settings. This paper offers a global perspective on the use of the scales and how they contribute to addressing global healthcare challenges related to treatment adherence, hamper optimal healthcare outcomes. In particular, this review highlights the usability, translatability, and scalability of the HBCHBPT scales across multiple countries, populations, and cultures. This review also shows that the HBCHBPT scales can be administered by various healthcare work cadres, such as community health workers, etc., among diverse populations and in low resources healthcare settings; thus, presenting important evidence that the scales have been used globally to aid clinical decision-making.

Another major strength of the scale is its high clinical utility in personalized care; the scales have been used to guide personalized intervention based on individual adherence types (intentional vs non-intentional). For instance, educational intervention can be provided to people who are intentionally not taking medications due to myths or insufficient knowledge.74 For people who are missing medications due to unintentional reasons (eg, cognitive decline, busy schedule), habit forming (cognitive-behavioral) intervention was applied.74 The HBCHBT scale has an adequate number of items that allow researchers and clinicians to identify the causes of their adherence barriers. Given that the field is moving to precision health paradigm, the ability of the scale to phenotype adherence is critical and can be a basis for precision and personalized intervention, according to psychosocial phenotyping) to improve adherence to high blood pressure treatment regimen.

This study has revealed some weaknesses of the scale. The appointment-keeping and salt intake subscales suffer from relatively low item-to-total correlations or low Cronbach’s α due to low numbers of items in those subscales. To continue to be a comprehensive adherence measure for high blood pressure self-management support programs, those subscales should be considered to add a few theoretically meaningful and behaviorally relevant items.

Conclusion

The reported validity and reliability measures for the HBCHBPT scales continue to vary slightly across settings, highlighting the need for better psychometric properties. Due to the heterogeneity of the data collection methods, analyses, and follow-up times, we could not obtain an overall effect size through a meta-analysis. Studies varied in terms of treatment groups, follow-up times, and outcomes. Moreover, few RCT studies measured medication adherence as an outcome. Despite these drawbacks, our systematic review has some strengths. To our knowledge, this is the first review providing a systematic evaluation of the use of the HBCHBPT scale across different contexts. We have provided contemporary evidence on the scales’ psychometric properties in studies examining different health conditions and behaviors. Translation of the original English version of the HBCHBPT scale into 25 different languages, did not compromise the clinical utility of the scale. We have also demonstrated the versatility of the scale and reach across six different World Health Organization (WHO) regions.

Acknowledgments

The Hill-Bone Compliance to Blood Pressure Therapy Scale was created through grant funding from the National Institutes of Health (NIH).

Disclosure

Ms Lauren Smulcer reports being the spouse of an active duty Army officer; her spouse receives salary from the federal government as an active duty soldier. The authors report no other conflicts of interest in this work.

References

  • 1.Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics—2023 update: a report from the American heart association. Circulation. 2023;147(8):e93–e621. doi: 10.1161/CIR.0000000000001123 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Carey RM, Aronow WS, Casey DE, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines. Nnals Inter Med. 2018;168:1524–4563. [Google Scholar]
  • 3.Follow up Program Cooperative Grou. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension detection and follow-up program cooperative group. JAMA. 1979;242:0098–7484. [PubMed] [Google Scholar]
  • 4.SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265:0098–7484. [PubMed] [Google Scholar]
  • 5.Elliott WJ. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypert. 2008;10:1524–6175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Osterberg L, Blaschke T. Adherence to medication. New Engl J Med. 2005;353:1533–4406. [DOI] [PubMed] [Google Scholar]
  • 7.van der Laan DM, Elders PJM, Boons C, Beckeringh JJ, Nijpels G, Hugtenburg JG. Factors associated with antihypertensive medication non-adherence: a systematic review. J Human Hypert. 2017;31:1476–5527. [DOI] [PubMed] [Google Scholar]
  • 8.Ogungbe O, Himmelfarb CR, Commodore-Mensah Y. Improving medication adherence in cardiovascular disease prevention: what’s new? J Cardiovasc Nurs. 2020;2020:1550–5049. [DOI] [PubMed] [Google Scholar]
  • 9.Ogungbe O, Byiringiro S, Adedokun-Afolayan A, et al. Medication adherence interventions for cardiovascular disease in low- and middle-income countries: a systematic review. Patient Prefer Adher. 2021;2021:1177–889X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Marcum ZA, Sevick MA, Handler SM. Medication nonadherence: a diagnosable and treatable medical condition. JAMA. 2013;309(20):2105–2106. doi: 10.1001/jama.2013.4638 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.MacLaughlin EJ, Raehl Cl Fau - Treadway AK, Treadway Ak Fau - Sterling TL, Sterling Tl Fau - Zoller DP, Zoller Dp Fau - Bond CA, Bond CA. Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging. 2005;22:1170–229X. [DOI] [PubMed] [Google Scholar]
  • 12.Wagner JH, Justice Ac Fau - Chesney M, Chesney M, et al. Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. J Clinl Epidemiol. 2001;54:0895–4356. [DOI] [PubMed] [Google Scholar]
  • 13.Kelly MS, Moczygemba LR, Gatewood SS. Concordance of pharmacist assessment of medication nonadherence with a self-report medication adherence scale. J Pharm Pract. 2016;29:1531–1937. [DOI] [PubMed] [Google Scholar]
  • 14.Nguyen TM, La Caze A, Fau - Cottrell N, Cottrell N. What are validated self-report adherence scales really measuring?: a systematic review. Br J Clin Pharmacol. 2014;77:1365–2125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kim MT, Levine DM. Development and testing of the hill-bone compliance to high blood pressure therapy scale. Prog Cardiov Nurs. 2000;2000:0889–7204. [DOI] [PubMed] [Google Scholar]
  • 16.Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Veritas health innovation; Available from: www.covidence.org. Accessed September 01, 2023.
  • 18.Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Anna Inter Med. 2011;155:1539–3704. [DOI] [PubMed] [Google Scholar]
  • 19.Abel WM, Crane PB, McCoy T. Predictors of depression in black women with hypertension. Issu Ment Health Nurs. 2014;35:1096–4673. [DOI] [PubMed] [Google Scholar]
  • 20.Al-daken LI, Eshah NF. Self-reported adherence to therapeutic regimens among patients with hypertension. Clin Exp Hypertens. 2017;39(3):264–270. doi: 10.1080/10641963.2016.1247164 [DOI] [PubMed] [Google Scholar]
  • 21.Alsolami F, Hou X-Y, Correa-Velez I. An Arabic instrument to measure medication adherence in Saudi hypertensive patients. Middle East J Fam Med. 2013;11:17–23. doi: 10.5742/MEFM.2014.92409 [DOI] [Google Scholar]
  • 22.Asadullah IS, Ali H, Ul Haq N, Zarak MS, Nasim A. Assessment of medication adherence among hypertensive patients by using hill-bone compliance scale in tertiary care hospitals quetta. Indo Am J Pharm Sci. 2018;5(5):3796–3803. doi: 10.5281/zenodo.1248144 [DOI] [Google Scholar]
  • 23.Boulware LE, Carson KA, Troll MU, Powe NR, Cooper LA. Perceived susceptibility to chronic kidney disease among high-risk patients seen in primary care practices. J Gen Intern Med. 2009;24(10):1123–1129. doi: 10.1007/s11606-009-1086-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Chatziefstratiou A, Giakoumidakis K, Fotos NV, Baltopoulos G, Brokalaki H. Scales for assessing medication adherence in patients with hypertension. Br J Nurs. 2019;28(21):1388–1392. doi: 10.12968/bjon.2019.28.21.1388 [DOI] [PubMed] [Google Scholar]
  • 25.Cheong AT, Tong SF, Sazlina SG. Validity and reliability of the Malay version of the hill-bone compliance to high blood pressure therapy scale for use in primary healthcare settings in Malaysia: a cross-sectional study. Malays Fam Physician. 2015;10(2):36–44. [PMC free article] [PubMed] [Google Scholar]
  • 26.Chudiak A, Jankowska-Polańska B, Uchmanowicz I. Effect of frailty syndrome on treatment compliance in older hypertensive patients. Clin Interv Aging. 2017;12:805–814. doi: 10.2147/CIA.S126526 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Chudiak A, Uchmanowicz I, Mazur G. Relation between cognitive impairment and treatment adherence in elderly hypertensive patients. Clin Interv Aging. 2018;13:1409–1418. doi: 10.2147/CIA.S162701 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Dennison CR, Peer N, Steyn K, Levitt NS, Hill MN. Determinants of hypertension care and control among peri-urban Black South Africans: the HIHI study. Ethn Dis. 2007;17(3):484–491. [PubMed] [Google Scholar]
  • 29.Dharan DR, Moly KT. Factors influencing compliance to therapeutic regimen among patients with hypertension. Asian J Pharm Clin Res. 2017;10(12):286–289. doi: 10.22159/ajpcr.2017.v10i12.21034 [DOI] [Google Scholar]
  • 30.Etebari F, Pezeshki MZ, Fakour S. Factors related to the non-adherence of medication and nonpharmacological recommendations in high blood pressure patients. J Cardiovasc Thorac Res. 2019;11(1):28–34. doi: 10.15171/jcvtr.2019.05 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Fleig SV, Weger B, Haller H, Limbourg FP. Effectiveness of a fixed-dose, single-pill combination of perindopril and amlodipine in patients with hypertension: a non-interventional study. Adv Ther. 2018;35(3):353–366. doi: 10.1007/s12325-018-0675-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Fongwa MN, Nandy K, Qing Y, Hays RD. The facilitators of and barriers to adherence to hypertension treatment scale. J Cardiovasc Nurs. 2015;30(6):484–490. doi: 10.1097/JCN.0000000000000206 [DOI] [PubMed] [Google Scholar]
  • 33.Gerber BS, Cho YI, Arozullah AM, et al. Racial differences in medication adherence: a cross-sectional study of Medicare enrollees. Am J Geriat Pharmacoth. 2010;8:1876–7761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Glasgow RE, Kurz D, King D, et al. Twelve-month outcomes of an internet-based diabetes self-management support program. Patient Educ Couns. 2012;87(1):81–92. doi: 10.1016/j.pec.2011.07.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Greer DB, Abel WM. Religious/Spiritual Coping in Older African American Women. Qual Rep. 2017;22(1):237–260. [Google Scholar]
  • 36.Greer DB, Ostwald SK. Improving adherence in African American women with uncontrolled hypertension. J Cardiovas Nurs. 2015;30:1550–5049. [DOI] [PubMed] [Google Scholar]
  • 37.Han H-R, Lee H, Commodore-Mensah Y, Kim M. Development and validation of the hypertension self-care profile: a practical tool to measure hypertension self-care. J Cardiovasc Nurs. 2014;29(3):E11–E20. doi: 10.1097/JCN.0b013e3182a3fd46 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Hill-Briggs F, Gary TL, Yeh HC, et al. Association of social problem solving with glycemic control in a sample of urban African Americans with type 2 diabetes. J Behav Med. 2006;29:0160–7715. [DOI] [PubMed] [Google Scholar]
  • 39.Hsu Y-H, Mao C-L, Wey M. Antihypertensive medication adherence among elderly Chinese Americans. J Transcult Nurs. 2010;21(4):297–305. doi: 10.1177/1043659609360707 [DOI] [PubMed] [Google Scholar]
  • 40.Ingram RR, Ivanov LL. Examining the association of health literacy and health behaviors in African American older adults: does health literacy affect adherence to antihypertensive regimens? J Gerontol Nurs. 2013;39(3):22–32; quiz 33. doi: 10.3928/00989134-20130201-01 [DOI] [PubMed] [Google Scholar]
  • 41.Karademir M, Koseoglu IH, Vatansever K, Van Den Akker M. Validity and reliability of the Turkish version of the HillBone compliance to high blood pressure therapy scale for use in primary health care settings. Eur J Gen Pract. 2009;15(4):207–211. doi: 10.3109/13814780903452150 [DOI] [PubMed] [Google Scholar]
  • 42.Kim E-Y, Han H-R, Jeong S, et al. Does knowledge matter? Intentional medication nonadherence among middle-aged Korean Americans with high blood pressure. J Cardiovasc Nurs. 2007;22(5):397–404. doi: 10.1097/01.JCN.0000287038.23186.bd [DOI] [PubMed] [Google Scholar]
  • 43.Koschack J, Marx G, Schnakenberg J, Kochen MM, Himmel W. Comparison of two self-rating instruments for medication adherence assessment in hypertension revealed insufficient psychometric properties. J Clin Epidemiol. 2010;63(3):299–306. doi: 10.1016/j.jclinepi.2009.06.011 [DOI] [PubMed] [Google Scholar]
  • 44.Krousel-Wood M, Muntner P, Jannu A, Desalvo K, Re RN. Reliability of a medication adherence measure in an outpatient setting. Am J Med Sci. 2005;330(3):128–133. doi: 10.1097/00000441-200509000-00006 [DOI] [PubMed] [Google Scholar]
  • 45.Krousel-Wood MA, Islam T, Muntner P, et al. Medication adherence in older clinic patients with hypertension after Hurricane Katrina: implications for clinical practice and disaster management. Am J Med Sci. 2008;336(2):99–104. doi: 10.1097/MAJ.0b013e318180f14f [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Krousel-Wood M, Joyce C, Holt EW, et al. Development and evaluation of a self-report tool to predict low pharmacy refill adherence in elderly patients with uncontrolled hypertension. Pharmacotherapy. 2013;33(8):798–811. doi: 10.1002/phar.1275 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Lambert EV, Steyn K, Stender S, Everage N, Fourie JM, Hill M. Cross-cultural validation of the hill-bone compliance to high blood pressure therapy scale in a South African, primary healthcare setting. Ethn Dis. 2006;16(1):286–291. [PubMed] [Google Scholar]
  • 48.Mafutha GN, Wright SC. Compliance or non-compliance of hypertensive adults to hypertension management at three primary healthcare day clinics in Tshwane. Curationis. 2013;36(1):E1–E6. doi: 10.4102/curationis.v36i1.52 [DOI] [PubMed] [Google Scholar]
  • 49.Manze MG, Orner MB, Glickman M, Pbert L, Berlowitz D, Kressin NR. Brief provider communication skills training fails to impact patient hypertension outcomes. Patient Educ Couns. 2015;98(2):191–198. doi: 10.1016/j.pec.2014.10.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Maslakpak MH, Rezaei B, Parizad N. Does family involvement in patient education improve hypertension management? A single-blind randomized, parallel group, controlled trial. Cogent Med. 2018;5(1):1537063. doi: 10.1080/2331205X.2018.1537063 [DOI] [Google Scholar]
  • 51.Mutneja E, Yadav R, Dey AB, Gupta P. Frequency and predictors of compliance among patients taking antihypertensive medicines. Indian Heart J. 2020;72:136–139. doi: 10.1016/j.ihj.2020.03.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Nashilongo MM, Singu B, Kalemeera F, et al. Assessing adherence to antihypertensive therapy in primary health care in Namibia: findings and implications. Cardiovasc Drugs Ther. 2017;31(5–6):565–578. doi: 10.1007/s10557-017-6756-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Ndumele CD, Shaykevich S, Williams D, Hicks LS. Disparities in adherence to hypertensive care in urban ambulatory settings. J Health Care Poor Underserved. 2010;21(1):132–143. doi: 10.1353/hpu.0.0259 [DOI] [PubMed] [Google Scholar]
  • 54.Nguyen GC, LaVeist TA, Harris ML, Datta LW, Bayles TM, Brant SR. Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(8):1233–1239. doi: 10.1002/ibd.20883 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Nogueira-Silva L, Sá-Sousa A, Lima MJ, Monteiro A, Dennison-Himmelfarb C, Fonseca JA. Translation and cultural adaptation of the hill-bone compliance to high blood pressure therapy scale to Portuguese. Rev Port Cardiol. 2016;35(2):93–97. doi: 10.1016/j.repc.2015.07.013 [DOI] [PubMed] [Google Scholar]
  • 56.Rose LE, Sawyer AL, Everett A. Cardiovascular health literacy and treatment adherence in persons with serious mental illness. Issues Ment Health Nurs. 2014;35(2):88–99. doi: 10.3109/01612840.2013.843622 [DOI] [PubMed] [Google Scholar]
  • 57.Sarfo FS, Mobula LM, Burnham G, et al. Factors associated with uncontrolled blood pressure among Ghanaians: evidence from a multicenter hospital-based study. PLoS One. 2018;13(3):e0193494. doi: 10.1371/journal.pone.0193494 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Shawler C, Edward J, Ling J, Crawford TN, Rayens MK. Impact of mother-daughter relationship on hypertension self-management and quality of life: testing dyadic dynamics using the actor-partner interdependence model. J Cardiovasc Nurs. 2018;33(3):232–238. doi: 10.1097/JCN.0000000000000448 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Song Y, Han HR, Song HJ, Nam S, Nguyen T, Kim MT. Psychometric evaluation of hill-bone medication adherence subscale. Asian Nurs Res. 2011;5(3):183–188. doi: 10.1016/j.anr.2011.09.007 [DOI] [PubMed] [Google Scholar]
  • 60.Uchmanowicz I, Jankowska-Polańska B, Chudiak A, Szymańska-Chabowska A, Mazur G. Psychometric evaluation of the polish adaptation of the hill-bone compliance to high blood pressure therapy scale. BMC Cardiovasc Disord. 2016;16(1). doi: 10.1186/s12872-016-0270-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Uchmanowicz B, Chudiak A, Mazur G. The influence of quality of life on the level of adherence to therapeutic recommendations among elderly hypertensive patients. Patient Prefer Adherence. 2018;12:2593–2603. doi: 10.2147/ppa.S182172 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Uchmanowicz B, Chudiak A, Uchmanowicz I, Rosińczuk J, Froelicher ES. Factors influencing adherence to treatment in older adults with hypertension. Clin Interv Aging. 2018;13:2425–2441. doi: 10.2147/CIA.S182881 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Uchmanowicz B, Chudiak A, Uchmanowicz I, Mazur G. How may coexisting frailty influence adherence to treatment in elderly hypertensive patients? Int J Hypertens. 2019;2019:1–8. doi: 10.1155/2019/5245184 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Wang X, Robinson KM, Hardin HK. The impact of caregiving on caregivers’ medication adherence and appointment keeping. West J Nurs Res. 2015;37(12):1548–1562. doi: 10.1177/0193945914533158 [DOI] [PubMed] [Google Scholar]
  • 65.Zabihi RE, Ashktorab T, Banaderakhshan H, Zaeri F. Adherence to therapeutic regimens in patients with hypertension. ARYA Atheroscler. 2012;8:S190–S194. [Google Scholar]
  • 66.Zare S, Rezaee R, Aslani A, Shirdeli M, Kojuri J. Moving toward community based telehealth services using mhealth for hypertensive patients. Int J Technol Assess Health Care. 2019;35(5):379–383. doi: 10.1017/S0266462319000655 [DOI] [PubMed] [Google Scholar]
  • 67.Zwar N, Hermiz O, Halcomb E, Davidson PM, Bodenheimer T. Improving blood pressure control in general practice: a pilot study of the ImPress intervention. Aust Fam Physician. 2017;46(5):306–311. [PubMed] [Google Scholar]
  • 68.Culig J, Leppée M. From Morisky to Hill-bone; self-reports scales for measuring adherence to medication. Colleg Antropolog. 2014;38:0350–6134. [PubMed] [Google Scholar]
  • 69.Gehi AK, Ali S, Fau - Na B, Na B, Fau - Whooley MA, Whooley MA. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Arch Inter Med. 2007;167:0003–9926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Hamdidouche I, Jullien V, Laurent S, Azizi M. Detecting nonadherence to antihypertensive treatment. Hypertension. 2017;70(2):257–258. doi: 10.1161/HYPERTENSIONAHA.117.09739 [DOI] [PubMed] [Google Scholar]
  • 71.Kronish IM, Ye S. Adherence to cardiovascular medications: lessons learned and future directions. Prog Cardiov Dis. 2013;55:1873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.The hill-bone scales: hypertension and medication adherence scales. Available from: https://nursing.jhu.edu/faculty_research/research/projects/hill-bone/hill-bone-scales.html. Accessed September 01, 2023.
  • 73.Gabriel A, Zare H, Jones W, et al. Evaluating depressive symptoms among low-socioeconomic-status African American women aged 40 to 75 years with uncontrolled hypertension: a secondary analysis of a randomized clinical trial. JAMA psychiatry. 2021;78:2168–6238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Kim EY, Han HR, Jeong S, et al. Does knowledge matter?: intentional medication nonadherence among middle-aged Korean Americans with high blood pressure. J Cardiovas Nurs. 2007;22:1550–5049. [DOI] [PubMed] [Google Scholar]
  • 75.Zhang J, Gong Y, Zhao Y, Jiang N, Wang J, Yin XA-O. Post-stroke medication adherence and persistence rates: a meta-analysis of observational studies. J Neurol. 2021;268:1432–1459. [DOI] [PubMed] [Google Scholar]
  • 76.Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adher. 2016;2016:1177–889X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Smith D, Lovell J, Weller C, et al. A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PLoS One. 2017;12:1932–6203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Jackson CA, Clatworthy J, Fau - Robinson A, Robinson A, Fau - Horne R, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Official J Am Coll Gastroenterol. 2010;105:1572. [DOI] [PubMed] [Google Scholar]
  • 79.Mechta Nielsen T, Frøjk Juhl M, Feldt-Rasmussen B, Thomsen T. Adherence to medication in patients with chronic kidney disease: a systematic review of qualitative research. Clin Kidney J. 2018;11:2048–8505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Stewart BJ, Archbold PG. Focus on psychometrics nursing intervention studies require outcome measures that are sensitive to change: part one. Res Nurs Health. 1992;15(6):477–481. doi: 10.1002/nur.4770150610 [DOI] [PubMed] [Google Scholar]
  • 81.Stewart BJ, Archbold PG. Nursing intervention studies require outcome measures that are sensitive to change: part two. Res Nurs Health. 1993;16(1):77–81. doi: 10.1002/nur.4770160110 [DOI] [PubMed] [Google Scholar]
  • 82.Morisky DE, Ang A, Krousel‐Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hyperten. 2008;10:1524–6175. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 83.Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care. 1986;1986:0025–7079. [DOI] [PubMed] [Google Scholar]
  • 84.Ogedegbe G, Mancuso CA, Allegrante JP, Charlson ME. Development and evaluation of a medication adherence self-efficacy scale in hypertensive African-American patients. JClin Epidemiol. 2003;56(6):520. [DOI] [PubMed] [Google Scholar]
  • 85.Basu S, Garg S, Sharma N, Singh MM. Improving the assessment of medication adherence: challenges and considerations with a focus on low-resource settings. Tzu-Chi Medical J. 2019;31:1016–3190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. N Engl J Med. 2020;383(2):120–128. doi: 10.1056/NEJMoa2015432 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Patient preference and adherence are provided here courtesy of Dove Press

RESOURCES